Recce Pharmaceuticals
在场
Recce Pharmaceuticals 是一家在股票代码 RCE (AU) 下上市的公司。
高管
查看带有其 11 名主要高管的组织结构图
Recce Pharmaceuticals 搜索最多的简介
- James Graham, Managing Director & Chief Executive Officer
- Alistair McKeough, Non-Executive Director
- John Prendergast, Non-Executive Chairman of the Board
创建提醒
跟踪 Recce Pharmaceuticals 的高管变动
药店
Recce Pharmaceuticals 拥有 1,842 家竞争者，其中包括 Pfizer (美国(美洲))、Johnson & Johnson (美国(美洲)) 和 Sanofi (法国)。
Popular M&A news in 药店
- BeiGene将改名为BeOne Medicines。 (公布2024十一月15号).
- GlycoMimetics and Crescent Biopharma have announced they will merge (公布2024十一月15号)..
- Grace Therapeutics将在Oct 25, 2024将其名称改为Grace Therapeutics。 (公布2024十月27号).
药店 行业的其他推荐联系人
消息
Recce Pharmaceuticals 的最新新闻稿
- Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger
- Recce Pharmaceuticals granted US$2 million from US Department of Defense for RECCE® 327 Gel
- Recce Pharmaceuticals more than doubles SPP target with A$4.4 million taking raise proceeds to A$12.4 million
- Recce Pharmaceuticals lands WHO Antibacterial Products in Clinical Development listing for RECCE® 327
- Recce Pharmaceuticals reports positive data from Phase 1/2 UTI/urosepsis rapid infusion clinical trial of RECCE® 327
- Recce Starts Phase 2 R327 Gel trial for bacterial skin infections
- Recce Pharmaceuticals makes breakthrough in lung infection treatment with nebulised RECCE® 327
- Recce Pharmaceuticals selected to participate in UK Government Innovation Agency’s AMR Mission 2024
- Recce gearing up for Indonesian trials; US DOD looking at R327 burn gel
- Recce reaches testing milestone for UTI, Uroseptis antibiotic
- View more press releases Close
通过电子邮件
